Navigation Links
Regular, long-term aspirin use reduces risk of colorectal cancer
Date:1/22/2008

Bethesda, MD (Jan. 18, 2008) The use of regular, long-term aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk associated with colorectal cancer, according to a study published in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. However, the use of aspirin for chemoprevention of colorectal cancer may require using the drug at doses that are higher than recommended over a long period of time, which may cause serious side effects including gastrointestinal bleeding.

While the results of our study show that aspirin should not currently be recommended for the chemoprevention of colorectal cancer in a healthy population, there is a need for further studies to help identify for which patients the potential benefits outweigh the risks, according to Andrew T. Chan, MD, MPH, Massachusetts General Hospital and lead author of the study. We also need to improve our understanding of how aspirin works to prevent and inhibit the formation of colorectal cancer.

Study participants were enrolled in the Health Professionals Follow-up Study, a large prospective cohort study which has provided detailed and updated information on aspirin use.

Researchers found that men who used aspirin regularly experienced a significantly lower risk of colorectal cancer, including distal colon cancer, proximal colon cancer and rectal cancer, even after controlling for other risk factors. The reduction in risk was seen in both early (stage I/II) and advanced (stage III/IV) colorectal cancers. There were 975 documented cases of colorectal cancer over 761,757 person-years, among the 47,636 eligible men. Participants who reported regular aspirin use, equal to or more than twice a week, were older, more likely to have smoked, used multivitamins and folate, and consumed slightly more alcohol.

In an average-risk population of men, results showed that the benefit of aspirin was not apparent until after more than five years of use. The greatest reduction in risk was observed at cumulative doses of more than 14 standard tablets (325 mg) per week, which is higher than normally recommended. The benefit of aspirin use appears to diminish less than four years after stopping use and is not evident after four to five years of discontinued use.

The Health Professionals Follow-up Study has been conducted on 51,529 U.S. male dentists, optometrists, osteopaths, podiatrists, pharmacists and veterinarians, who returned a mailed health questionnaire in 1986. The questionnaire included questions about diet, aspirin use and medical diagnoses, including cancer. The biennial questionnaires ask for updated information including cancer diagnoses and aspirin use. The participants were between 40 and 75 years of age when the study began.

This year an estimated 147,000 Americans will be diagnosed with colorectal cancer and 56,500 will die from this disease, with an approximate 1-in-18 lifetime probability of developing colorectal cancer.


'/>"/>

Contact: Aimee Frank
media@gastro.org
301-941-2620
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Long-Term Fatigue Plagues Cancer Survivors
3. Dont Ignore Tough or Long-Term Stomach Pain
4. Shaking may cause brain damage and serious long-term effects to infants
5. Sexual function affected by stem cell transplant according to long-term study
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Childhood Obesity Epidemic a Long-Term Challenge
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care
10. No Link Between Amateur Boxing, Long-Term Brain Damage
11. No strong evidence linking amateur boxing with long-term brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... MiracleFeet announced today ... years to help end the disability caused by untreated clubfoot in low-income countries. ... Global Clubfoot Initiative to end disability caused by clubfoot worldwide. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology: